Strategic trade
Trade view / 25 July 2016 at 14:28 GMT

#SaxoStrats: A bullish options play in Gilead Sciences

Head of Equity Strategy / Saxo Bank

As we wrote in our latest earnings watch, we are bullish on Gilead Sciences (one of the four mature US biotechnology firms) despite disappointing pipeline news. The expected free cash flow over the next six years is sufficient to cover the current market value, so the current share price has likely hit the floor with limited downside risk. 

Gilead Sciences shares are also on our global top 40 list in our monthly Alpha Picks publication.

With expectations as low as they are, there is the possibility of an upside surprise to the Q2 earnings to be released tonight after the US market close.

Gilead Sciences weekly share price since Q4 2011:

Create your own charts with SaxoTraderGO click here to learn more

Source: Saxo Bank 

Buy four-day call spread

We have before been long Gilead Sciences but closed the position in April with a 10.5% profit after costs. However, the US presidential election is still a drag on the biotechnology industry due to the potential downside risk on drug prices post the election. As a result, we hesitated to establish a new long position again. But with the recent Biogen surprise in Q2, Gilead Sciences may follow up with a surprise as well. ..
The best way to express a positive view on Gilead Sciences that is short-term in nature and has limited downside risk is through a call spread. In particular we like buying the call with its strike at $88 (mid-price is around $1.48) financed partly by selling the strike at $92 (mid-price around $0.39) – both options with expiry at 2016-07-29. 

So the downside is slightly above $1 with a potential $4 gain before costs. The key risk is Q2 earnings missing estimates and a dim outlook. In that case, the net premium ($1.48 - $0.39) x 100 = $109 per contract excluding commission is the maximum loss.

— Edited by Michael McKenna

For more on equities click here.

Non-independent investment research disclaimer applies. Read more
26 July
KaranKK KaranKK
Hey Peter,
Most of the content you post is outdated. Its a direct copy from Bloomberg & CNBC - Old stories.
Example - The trade you talked yesterday about Gilead Sciences was stale trade on Bloomberg 4 days back.
Beginning to loose confidence now...See yourself this link ....


The Saxo Bank Group entities each provide execution-only service and access to permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on or as a result of the use of the Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. When trading through your contracting Saxo Bank Group entity will be the counterparty to any trading entered into by you. does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of ourtrading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws. Please read our disclaimers:
- Notification on Non-Independent Invetment Research
- Full disclaimer

Check your inbox for a mail from us to fully activate your profile. No mail? Have us re-send your verification mail